Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Foss

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Annals of the New York Academy of Sciences|October 12, 2001
Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphomaF M Foss
Seminars in Oncology|July 6, 2000
Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studiesF M Foss
Clinical Lymphoma|November 15, 2001
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphomaF M Foss
Clinical Lymphoma|November 15, 2001
An oncologist's approach to therapy for cutaneous T-cell lymphomaF M Foss
Clinical Lymphoma|November 15, 2001
DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technologyF M Foss
Oncology (Williston Park, N.Y.)|July 11, 2000
Combination therapy with purine nucleoside analogsF M Foss
Hematology/Oncology Clinics of North America|October 1, 1995
Experimental therapies in the treatment of cutaneous T-cell lymphomaF M Foss, T M Kuzel
Journal of Cellular Biochemistry. Supplement|January 1, 1996
T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL)P A Bunn, F M Foss
Hematology/Oncology Clinics of North America|October 1, 1995
Chemotherapy for mycosis fungoides and the Sézary syndromeS T Rosen, F M Foss
Hematology/Oncology Clinics of North America|October 1, 1995
Prognosis and staging of cutaneous T-cell lymphomaF M Foss, E A Sausville
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Annals of the New York Academy of Sciences|October 12, 2001
Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphomaF M Foss
Seminars in Oncology|July 6, 2000
Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studiesF M Foss
Clinical Lymphoma|November 15, 2001
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphomaF M Foss
Clinical Lymphoma|November 15, 2001
An oncologist's approach to therapy for cutaneous T-cell lymphomaF M Foss
Clinical Lymphoma|November 15, 2001
DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technologyF M Foss
Oncology (Williston Park, N.Y.)|July 11, 2000
Combination therapy with purine nucleoside analogsF M Foss
Hematology/Oncology Clinics of North America|October 1, 1995
Experimental therapies in the treatment of cutaneous T-cell lymphomaF M Foss, T M Kuzel
Journal of Cellular Biochemistry. Supplement|January 1, 1996
T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL)P A Bunn, F M Foss
Hematology/Oncology Clinics of North America|October 1, 1995
Chemotherapy for mycosis fungoides and the Sézary syndromeS T Rosen, F M Foss
Hematology/Oncology Clinics of North America|October 1, 1995
Prognosis and staging of cutaneous T-cell lymphomaF M Foss, E A Sausville
Pageof 4